StuCNS Response REEG-Guidance For Resistant Depression Superior To APA Guidelines Most Commonly Used By Payers, Study

CNS Response, Inc.
(OTCBB: CNSO) reported the results of a study by the Center for
Health Economics, Epidemiology, and Science Policy at United
BioSource Corporation, a global pharmacoeconomic research firm and
one of the most experienced firms providing evidence-based review of
innovative healthcare technologies.



The study, entitled "Comparing Levels of Evidence for Treatment of
Treatment-Resistant Depression with Referenced-EEG(R) to Current
Practice," analyzed published studies on treatment-resistant
depression (TRD), and modeled the evidence for Referenced-EEG (rEEG)
against evidence for currently reimbursed therapies. The study is
available on the CNS Response website, cnsresponse.



Evidence supporting rEEG appears superior to that supporting APA
(American Psychiatric Association) or TMAP (Texas Medication Algorithm
Project) treatment guidelines, wrote investigator Mkaya Mwamburi, MD,
PhD. "The findings of this project provide a compelling basis for the
consideration of rEEG as a beneficial modality of medication selection
for the treatment of TRD. These findings may warrant the
consideration of rEEG for inclusion in treatment guidelines and
perhaps a basis for re-imbursement," concluded Dr. Mwamburi.



Depression affects 18.8 million people in the U.S. The financial
implications of the disease are extraordinary, estimated at $83
billion annually, including the cost of more than 11.4 million
prescriptions for depression being written by physicians monthly.



"This study has broad implications for payers who believe there is
adequate evidence supporting therapies they reimburse," commented
George Carpenter, President of CNS Response. "But numerous studies,
such as STAR*D (Sequenced Treatment Alternatives to Relieve
Depression), have demonstrated high failure rates and very little
evidence for the treatment of TRD patients. The published evidence on
rEEG, as assessed by United BioSource, compares favorably in academic
rigor and clinical outcomes. Payers utilizing rEEG can now pay for
treatments with better patient outcomes, lower costs, and superior
evidence," added Carpenter.



Consulting Actuary Steve Melek of Milliman Global noted, "The impact
on payers couldn't come at a better time. The $30 billion U.S. payers
spend on retail prescription drugs for mental disorders is frequently
ineffective in achieving disease remission. With the passage of
mental health parity legislation, there is a great opportunity for
improvement in effective diagnosis and treatment of depression, both
in primary and specialty care settings. Payers could greatly benefit
from such improvements, leading to better clinical and financial
outcomes."
















"In summary," said CNS Response CEO Len Brandt, "United BioSource
Corporation is one of the most experienced and trusted firms for
evidence-based review of innovative healthcare technologies. With the
recent passing of legislation mandating that behavioral care now be
treated on parity with other medical care, we believe the United
BioSource analysis of rEEG and the Analysis Group's recent rEEG
economic impact study arms corporations, their insurance companies,
and managed care vendors with the knowledge that rEEG is
evidence-supported and economically beneficial to all concerned. We
are positioned to provide significant benefit to patients, payers and
providers."



About CNS Response



CNS Response is a life-sciences data company whose patented system
provides treatment guidance to psychiatrists and other physicians for
patients with behavioral (mental or addictive) disorders. This
technology allows CNS Response to create and provide simple reports
("rEEG(R) Reports") that specifically guide physicians to treatment
strategies based on the patient's own physiology.



rEEG utilizes traditional electroencephalography (EEG) in conjunction
with a normative database and a proprietary clinical (symptomatic)
database to identify the following: (1) medication classes most
likely to be needed; and (2) medications within these classes with
the most probable treatment potential for each patient. Reports are
provided to physicians in a relationship analogous to that of a
reference laboratory. Prospective, retrospective and field studies of
treatment-resistant patients have reported treatment success of 70%
or greater in managed care, outpatient psychiatric and residential
substance abuse clinical settings.



In addition to providing analytical support to physicians, CNS
Response is also an aid to pharmaceutical developers, who can use
rEEG to (1) stratify study populations to improve the success of FDA
clinical trials; (2) provide insight on effective therapeutic dosing
of investigational drugs; (3) identify additional indications for
psychiatric medications; (4) provide insight into effective drug
combinations; and (5) discover opportunities for decision analytics
and support. In addition to these applications, CNS Response
continues to investigate the use of rEEG analysis for development of
proprietary pharmaceutical opportunities.



About United BioSource Corporation (UBC)



UBC is a global pharmaceutical services organization that helps
emerging and established life science companies develop and
commercialize medical products. UBC specializes in offering new and
innovative ways to study drugs and devices by providing expertise in
science, strategy and execution. UBC is headquartered in Bethesda,
Maryland, with offices in the United States, Canada, Eastern and
Western Europe and South America. For more information, visit
unitedbiosource or call +866-458-1096.



Safe Harbor Statement Under the Private Securities Litigation Reform
Act of 1995



Except for the historical information contained herein, the matters
discussed are forward-looking statements made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act of
1995, as amended. These statements involve risks and uncertainties as
set forth in the Company's filings with the Securities and Exchange
Commission. These risks and uncertainties could cause actual results
to differ materially from any forward-looking statements made herein.

United BioSource Corporation